Skip to main content
Erschienen in: Nuclear Medicine and Molecular Imaging 2/2019

02.04.2019 | Perspective

Theranostics in Bangladesh: Current Status, Challenges, and Future Perspective

verfasst von: Shamim Momtaz Ferdousi Begum, Lutfun Nisa, Azmal K. Sarker

Erschienen in: Nuclear Medicine and Molecular Imaging | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Background and Current Status of Theranostics

Therapeutic nuclear medicine (NM) in Bangladesh began in the early 1980s with the application of radioactive iodine for treatment of thyroid cancer and primary hyperthyroidism. Since then, NM practice has remarkably developed in the country with the advancement of instrumentation, radiopharmacy, and information technology. The government took the initiative to establish four PET-CT centers at different NM centers, including one at the National Institute of Nuclear Medicine and Allied Sciences (NINMAS). A further development is the installation of a cyclotron center (18-MeV cyclotron) at NINMAS by the government’s fund. Currently, NM is providing good health services to oncology patients throughout the country. More than 20 NM centers are functioning in different parts of the country, and therapeutic NM has an important place. However, conventional radioactive iodine still remains the major theranostic application.

Challenges and Future Perspective

The expansion and development of therapeutic NM for other cancers have been limited due to a number of challenging factors. A brief overview of the history and current status of NM in Bangladesh is presented here with an examination of factors that pose as obstacles to the introduction and development of new therapeutic technologies. Finally, future perspectives are discussed with ways to mitigate existing problems and challenges.
Literatur
1.
Zurück zum Zitat Hussain R. History and Perspectives of nuclear medicine in Bangladesh. Asia Oceania J Nucl Med Biol. 2016;4:5–8. Hussain R. History and Perspectives of nuclear medicine in Bangladesh. Asia Oceania J Nucl Med Biol. 2016;4:5–8.
2.
Zurück zum Zitat Hasan M. Present, Past and future of nuclear medicine in Bangladesh (editorial). Bangladesh J Nucl Med. 2014;17:8–9.CrossRef Hasan M. Present, Past and future of nuclear medicine in Bangladesh (editorial). Bangladesh J Nucl Med. 2014;17:8–9.CrossRef
5.
Zurück zum Zitat Afroz S, Hossain S, Hafiz N, Taslima DA, Rashid H. Radioiodine therapy in management of thyroid carcinoma—a review of 138 patients. IAEA-SR-209/6;1999. Afroz S, Hossain S, Hafiz N, Taslima DA, Rashid H. Radioiodine therapy in management of thyroid carcinoma—a review of 138 patients. IAEA-SR-209/6;1999.
6.
Zurück zum Zitat Sultana S, Nahar N, Begum F, Alam F, Hasan M, Hussain R, et al. Management of Patients with differentiated thyroid carcinoma—SNMB guidelines. Bangladesh J Nucl Med. 2015;18:73–84.CrossRef Sultana S, Nahar N, Begum F, Alam F, Hasan M, Hussain R, et al. Management of Patients with differentiated thyroid carcinoma—SNMB guidelines. Bangladesh J Nucl Med. 2015;18:73–84.CrossRef
7.
Zurück zum Zitat Hussain R, Sultana S, Jabin Z, Perveen R, Nath KK, Alam F. Outcome of strontium-90 irradiation on conjunctival squamous cell carcinoma: a 6-year experience [abstract]. World J Nucl Med. 2015;14(Suppl 1):S103–10. Hussain R, Sultana S, Jabin Z, Perveen R, Nath KK, Alam F. Outcome of strontium-90 irradiation on conjunctival squamous cell carcinoma: a 6-year experience [abstract]. World J Nucl Med. 2015;14(Suppl 1):S103–10.
8.
Zurück zum Zitat Alam F, Islam ASMM, Karim MA. Therapy protocol for thyroid cancer and thyrotoxicosis with I 131 adopted in the National Workshop on Management of Thyroid Cancer & Thyrotoxicosis by Nuclear Medicine Technique—a consensus report. Bangladesh J Nucl Med. 2002;5:39–42. Alam F, Islam ASMM, Karim MA. Therapy protocol for thyroid cancer and thyrotoxicosis with I 131 adopted in the National Workshop on Management of Thyroid Cancer & Thyrotoxicosis by Nuclear Medicine Technique—a consensus report. Bangladesh J Nucl Med. 2002;5:39–42.
9.
Zurück zum Zitat Begum F, Sultana S, Nahar N, Alam F, Hasan M, Hussain R, et al. Protocol for management of hyperthyroidism by radioactive iodine (RAIT)-SNMB guidelines. Bangladesh J Nucl Med. 2015;18:85–8.CrossRef Begum F, Sultana S, Nahar N, Alam F, Hasan M, Hussain R, et al. Protocol for management of hyperthyroidism by radioactive iodine (RAIT)-SNMB guidelines. Bangladesh J Nucl Med. 2015;18:85–8.CrossRef
10.
Zurück zum Zitat Adedapo KS, Onimode YA, Ejeh JE, Adepoju AO. Avoidable challenges of a nuclear medicine facility in a developing nation. Indian J Nucl Med. 2013;28:195–9.CrossRefPubMedPubMedCentral Adedapo KS, Onimode YA, Ejeh JE, Adepoju AO. Avoidable challenges of a nuclear medicine facility in a developing nation. Indian J Nucl Med. 2013;28:195–9.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Azim MA, Hasan M, Hossain R, Ansari IH, Nasreen F, Hossain N, et al. Production and therapeutic application of iodine-131 in nuclear medicine of Bangladesh: present status and future plan: current and future therapeutic radiopharmaceuticals [abstract]. World J Nucl Med. 2016;15(Suppl 1):S3–39. Azim MA, Hasan M, Hossain R, Ansari IH, Nasreen F, Hossain N, et al. Production and therapeutic application of iodine-131 in nuclear medicine of Bangladesh: present status and future plan: current and future therapeutic radiopharmaceuticals [abstract]. World J Nucl Med. 2016;15(Suppl 1):S3–39.
12.
Zurück zum Zitat Maj A. Thyroid disorders in Bangladesh—past, present and future [editorial]. J Dhaka Med Coll. 2014;23:151–2. Maj A. Thyroid disorders in Bangladesh—past, present and future [editorial]. J Dhaka Med Coll. 2014;23:151–2.
13.
Zurück zum Zitat Bangladesh Atomic Energy Regulatory Act 2012. Government of the People’s Republic of Bangladesh, Ministry of Science and Technology. Retrieved 15 Oct, 2018 from http://www.baera.gov.bd Bangladesh Atomic Energy Regulatory Act 2012. Government of the People’s Republic of Bangladesh, Ministry of Science and Technology. Retrieved 15 Oct, 2018 from http://​www.​baera.​gov.​bd
14.
Zurück zum Zitat Directorate General of Drug Administration MOHFW. Guidance on clinical trial inspection. Directorate General of Drug Administration MOHFW. Guidance on clinical trial inspection.
15.
Zurück zum Zitat Directorate General of Drug Administration MOHFW. Guidance for good clinical practice or trials on pharmaceutical products. Directorate General of Drug Administration MOHFW. Guidance for good clinical practice or trials on pharmaceutical products.
Metadaten
Titel
Theranostics in Bangladesh: Current Status, Challenges, and Future Perspective
verfasst von
Shamim Momtaz Ferdousi Begum
Lutfun Nisa
Azmal K. Sarker
Publikationsdatum
02.04.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Nuclear Medicine and Molecular Imaging / Ausgabe 2/2019
Print ISSN: 1869-3474
Elektronische ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-019-00590-1

Weitere Artikel der Ausgabe 2/2019

Nuclear Medicine and Molecular Imaging 2/2019 Zur Ausgabe